Nick publishes a commentary on the future of clinical trials

In this commentary Dr. Tatonetti argues for a different approach for monitoring drug safety in the marketplace that combines data from spontaneous reporting systems in humans with experiments in models systems. This approach has the speed and agility of observational research with the rigor and robustness of prospective trials. Read the whole commentary here.